Macitentan and morbidity and mortality in pulmonary arterial hypertension
Pulido, Tomás × Adzerikho, Igor Channick, Richard N Delcroix, Marion Galiè, Nazzareno Ghofrani, Hossein-Ardeschir Jansa, Pavel Jing, Zhi-Cheng Le Brun, Franck-Olivier Mehta, Sanjay Mittelholzer, Camilla M Perchenet, Loïc Sastry, B K S Sitbon, Olivier Souza, Rogério Torbicki, Adam Zeng, Xiaofeng Rubin, Lewis J Simonneau, Gérald SERAPHIN Investigators #
New England Journal of Medicine vol:369 issue:9 pages:809-818
Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.